Ema confirms acceptance of application for avt04, a proposed biosimilar to stelara® (ustekinumab)

Reykjavik, iceland and bad vilbel, germany, feb. 09, 2023 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and global pharmaceutical company stada arzneimittel (stada) today announced that the european medicines agency (ema) has accepted a marketing authorization application for avt04, alvotech's proposed biosimilar to stelara® (ustekinumab). the companies anticipate that the ema could recommend approving a marketing authorization for avt04 as soon as in the second half of 2023.
ALVO Ratings Summary
ALVO Quant Ranking